{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:23:26Z","timestamp":1773282206031,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40265-013-0073-8","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T13:47:27Z","timestamp":1370440047000},"page":"949-958","source":"Crossref","is-referenced-by-count":10,"title":["Loteprednol Etabonate Ophthalmic Gel 0.5\u00a0%: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery"],"prefix":"10.1007","volume":"73","author":[{"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,6]]},"reference":[{"issue":"1","key":"73_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","volume":"12","author":"SM El-Harazi","year":"2001","unstructured":"El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1):4\u20138.","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"73_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/112067210701700104","volume":"17","author":"M Mohammadpour","year":"2007","unstructured":"Mohammadpour M, Jafarinasab MR, Javadi MA. Outcomes of acute postoperative inflammation after cataract surgery. Eur J Ophthalmol. 2007;17(1):20\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"73_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10792-012-9589-2","volume":"32","author":"M Amon","year":"2012","unstructured":"Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012;32(5):507\u201317.","journal-title":"Int Ophthalmol"},{"key":"73_CR4","doi-asserted-by":"crossref","unstructured":"Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012. doi: 10.1155\/2012\/789623 .","DOI":"10.1155\/2012\/789623"},{"issue":"1","key":"73_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33\u201355.","journal-title":"Drug Saf"},{"key":"73_CR6","first-page":"299","volume":"7","author":"MJ Coffey","year":"2013","unstructured":"Coffey MJ, Decory HH, Lane SS. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop. Clin Ophthalmol. 2013;7:299\u2013312.","journal-title":"Clin Ophthalmol"},{"key":"73_CR7","volume-title":"Perferred Practice Pattern Guidelines\u00ae: cataract in the adult eye","author":"American Academy of Ophthalmology Cataract and Anterior Segment Panel","year":"2011","unstructured":"American Academy of Ophthalmology Cataract and Anterior Segment Panel. Perferred Practice Pattern Guidelines\u00ae: cataract in the adult eye. San Francisco: American Academy of Ophthalmology; 2011."},{"issue":"4","key":"73_CR8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","volume":"92","author":"CE Pavesio","year":"2008","unstructured":"Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455\u20139.","journal-title":"Br J Ophthalmol"},{"key":"73_CR9","unstructured":"Lotemax (loteprednol etabonate ophthalmic suspension 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2006."},{"key":"73_CR10","unstructured":"Lotemax (loteprednol etabonate ophthalmic ointment 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2011."},{"issue":"11","key":"73_CR11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","volume":"24","author":"R Stewart","year":"1998","unstructured":"Stewart R, Horwitz B, Howes J, et al. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24(11):1480\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"73_CR12","unstructured":"A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology. 1998;105(9):1780\u20136."},{"key":"73_CR13","first-page":"177","volume":"5","author":"TL Comstock","year":"2011","unstructured":"Comstock TL, Paterno, Singh A, et al. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177\u201386.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"73_CR14","first-page":"31","volume":"23","author":"P Asbell","year":"1997","unstructured":"Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J. 1997;23(1):31\u20136.","journal-title":"CLAO J"},{"issue":"4","key":"73_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9394(14)70171-0","volume":"123","author":"MH Friedlaender","year":"1997","unstructured":"Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123(4):455\u201364.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"73_CR16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","volume":"123","author":"SJ Dell","year":"1997","unstructured":"Dell SJ, Shulman DG, Lowry GM, et al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol. 1997;123(6):791\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"73_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444\u201357.","journal-title":"Am J Ophthalmol"},{"key":"73_CR18","unstructured":"Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127(5):537\u201344."},{"key":"73_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-7506-7576-5.50007-0","volume-title":"Clinical Ocular Pharmacology","author":"RG Fiscella","year":"2008","unstructured":"Fiscella RG. Ophthalmic drug formulations. In: Bartlett JD, Jaanus SD, editors. Clinical Ocular Pharmacology. 5th ed. St Louis: Butterworth-Heinemann; 2008. p. 17\u201337.","edition":"5"},{"key":"73_CR20","unstructured":"Lotemax (loteprednol etabonate ophthalmic gel 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2012."},{"issue":"1\u20132","key":"73_CR21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2007.05.019","volume":"275","author":"C Stahn","year":"2007","unstructured":"Stahn C, Lowenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275(1\u20132):71\u20138.","journal-title":"Mol Cell Endocrinol"},{"issue":"16","key":"73_CR22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"73_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jop.1994.10.3","volume":"10","author":"N Bodor","year":"1994","unstructured":"Bodor N. Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol. 1994;10(1):3\u201315.","journal-title":"J Ocul Pharmacol"},{"key":"73_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000422359","volume":"21","author":"N Bodor","year":"1993","unstructured":"Bodor N. Design of novel soft corticosteroids. Curr Probl Dermatol. 1993;21:11\u20139.","journal-title":"Curr Probl Dermatol"},{"issue":"4","key":"73_CR25","doi-asserted-by":"crossref","first-page":"E820","DOI":"10.1208\/aapsj070479","volume":"7","author":"N Bodor","year":"2005","unstructured":"Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7(4):E820\u201333.","journal-title":"AAPS J"},{"key":"73_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0960-0760(91)90120-T","volume":"38","author":"P Druzgala","year":"1991","unstructured":"Druzgala P, Hochhaus G, Bodor N. Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991;38:149\u201354.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"73_CR27","first-page":"115","volume":"2","author":"M Alberth","year":"1991","unstructured":"Alberth M, Wu WM, Winwood D, et al. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. J Biopharm Sci. 1991;2:115\u201325.","journal-title":"J Biopharm Sci"},{"key":"73_CR28","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2147\/OPTH.S32643","volume":"6","author":"R Fong","year":"2012","unstructured":"Fong R, Leitritz M, Siou-Mermet R, et al. Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol. 2012;6:1113\u201324.","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"73_CR29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcrs.2012.09.013","volume":"39","author":"RK Rajpal","year":"2013","unstructured":"Rajpal RK, Roel L, Siou-Mermet R, et al. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2013;39(2):158\u201367.","journal-title":"J Cataract Refract Surg"},{"issue":"9","key":"73_CR30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archopht.1980.01020040429006","volume":"98","author":"JS Mindel","year":"1980","unstructured":"Mindel JS, Tavitian HO, Smith H Jr, et al. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol. 1980;98(9):1577\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"73_CR31","first-page":"1123","volume":"30","author":"AS Bhargava","year":"1980","unstructured":"Bhargava AS, Staben P. Effect of corticosteroids on intraocular pressure, ascorbic acid and sialic acid concentrations in aqueous humour and on mucopolysaccharides biosynthesis in the cornea of rabbits. Arzneimittelforschung. 1980;30(7):1123\u20136.","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"73_CR32","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0002-9394(75)90687-X","volume":"79","author":"HL Cantrill","year":"1975","unstructured":"Cantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6):1012\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"73_CR33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/02713689209001808","volume":"11","author":"N Bodor","year":"1992","unstructured":"Bodor N, Bodor N, Wu WM. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res. 1992;11(6):525\u201330.","journal-title":"Curr Eye Res"},{"issue":"7","key":"73_CR34","first-page":"641","volume":"30","author":"J-S Wu","year":"2012","unstructured":"Wu J-S, Zhong X-W, Zhang X-X, et al. A randomized controlled study on the application of 0.5% loteprednol etabonate eye drops after LASIK surgery. Chin J Exp Ophthalomol. 2012;30(7):641\u20135.","journal-title":"Chin J Exp Ophthalomol"},{"key":"73_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1185\/030079908X253898","volume":"24","author":"EM White","year":"2008","unstructured":"White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol etabonate 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24:287\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"73_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.659723","volume":"28","author":"M Chen","year":"2012","unstructured":"Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%\/tobramycin 0.3% with dexamethasone 0.1%\/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin. 2012;28(3):1\u201310.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"73_CR37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/ICO.0b013e31815873c7","volume":"27","author":"EJ Holland","year":"2008","unstructured":"Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol\/tobramycin versus dexamethasone\/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27(1):50\u20135.","journal-title":"Cornea"},{"issue":"2","key":"73_CR38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcrs.2012.10.039","volume":"39","author":"SS Lane","year":"2013","unstructured":"Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39(2):168\u201373.","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"73_CR39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.1993.9.157","volume":"9","author":"JD Bartlett","year":"1993","unstructured":"Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9(2):157\u201365.","journal-title":"J Ocul Pharmacol"},{"issue":"10","key":"73_CR40","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/ICO.0b013e3181a3c52f","volume":"28","author":"EJ Holland","year":"2009","unstructured":"Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28(10):1139\u201343.","journal-title":"Cornea"},{"issue":"9","key":"73_CR41","first-page":"1792","volume":"10","author":"W-T Li","year":"2010","unstructured":"Li W-T, Li H, Wei J. Clinical study on the application of 5\u00a0g\/L loteprednol etabonate ophthalmic suspension after LASIK. Int J Ophthalmol. 2010;10(9):1792\u20133.","journal-title":"Int J Ophthalmol"},{"issue":"9","key":"73_CR42","first-page":"806","volume":"10","author":"D-H Gao","year":"2010","unstructured":"Gao D-H, Li K-J, Lu H. Clinical observations on the effect of lotemax on changes in intraocular pressure after LASEK. Int J Ophthalmol. 2010;10(9):806\u20137.","journal-title":"Int J Ophthalmol"},{"key":"73_CR43","unstructured":"Glogowski S, Proksch JW. Ocular and systemic pharmacokinetics of loteprednol etabonate gel (0.5%) following topical ocular administration to rabbits [poster no. D1138]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 6\u20139 May 2012, Fort Lauderdale."},{"key":"73_CR44","unstructured":"Aziz R. Pharmacology review(s): New Drug Application Number 202872 (loteprednol etabonate ophthalmic gel, 0.5%). Silver Spring: Center for Drug Evaluation and Research; 2012."},{"key":"73_CR45","unstructured":"Comstock TL, Siou-Mermet R, Erb T, et al. Efficacy of loteprednol etabonate gel 0.5% in the treatment of inflammation and pain in post-cataract surgery patients [poster no. 39]. Annual Meeting of the American Academy of Optometry; 24-27 Oct 2012, Phoenix."},{"key":"73_CR46","doi-asserted-by":"crossref","unstructured":"Rajpal RK, Siou-Mermet R, Erb T. Loteprednol etabonate (LE) gel 0.5% in the treatment of ocular inflammation and pain following cataract surgery [poster no. PO021]. Annual Meeting of the American Academy of Opthalmology; 10\u201313 Nov 2012, Chicago.","DOI":"10.1016\/j.jcrs.2012.09.013"},{"issue":"2","key":"73_CR47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0002-9394(79)90145-4","volume":"87","author":"L Apt","year":"1979","unstructured":"Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979;87(2):210\u20134.","journal-title":"Am J Ophthalmol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0073-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0073-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0073-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T19:05:56Z","timestamp":1563131156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0073-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0073-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}